Equities

Establishment Labs Holdings Inc

Establishment Labs Holdings Inc

Actions
Health CareMedical Equipment and Services
  • Price (USD)41.81
  • Today's Change4.29 / 11.43%
  • Shares traded2.00
  • 1 Year change+90.05%
  • Beta1.1594
Data delayed at least 15 minutes, as of Nov 20 2024 21:00 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Forecasts data is unavailable for this security.

Consensus recommendation

  • 14-Dec-23
  • 19-Sep-24
  • 17-Oct-24
  • 14-Nov-24
  • 18-Nov-24
Select bar for recommendation details.
Recommendations18-Nov-24
Buy3
Outperform3
Hold1
Sell0
Strong Sell0

Share price forecast in USD

The 7 analysts offering 12 month price targets for Establishment Labs Holdings Inc have a median target of 61.00, with a high estimate of 75.00 and a low estimate of 46.00. The median estimate represents a 45.90% increase from the last price of 41.81.
High79.4%75.00
Med45.9%61.00
Low10.0%46.00

Earnings history & estimates in USD

On Nov 07, 2024, Establishment Labs Holdings Inc reported 3rd quarter 2024 losses of -0.590 per share. This result was in line with the consensus of the 6 analysts following the company and exceeded last year's 3rd quarter results by 47.32%.
The next earnings announcement is expected on Feb 26, 2025.
Average growth rate+13.50%
Establishment Labs Holdings Inc reported annual 2023 losses of -3.07 per share on Feb 28, 2024.
Average growth rate-17.98%
More ▼

Revenue history & estimates in USD

Establishment Labs Holdings Inc. had 3rd quarter 2024 revenues of 40.23m. This missed the 40.45m consensus estimate of the 6 analysts following the company. This was 13.53% below the prior year's 3rd quarter results.
Average growth rate+2.40%
Establishment Labs Holdings Inc. had revenues for the full year 2023 of 165.15m. This was 2.13% above the prior year's results.
Average growth rate+18.48%
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.